title: Risk factors associated with the deterioration of renal function after kidney transplantation.
abstract: Renal function early after transplantation is associated with a large number of risk factors, including donor age and acute rejection. During the 1990s, donor age increased and the incidence of acute rejection decreased. Renal function between the third and sixth month improved slightly, while renal function deterioration between the third or sixth month and the 12th month improved significantly. This modification coincides with the introduction of mycophenolate mofetil and tacrolimus. The tendency for sustained renal improvement early after transplantation became more evident after the introduction of anti-calcineurin-free regimens. Studies of protocol biopsies have shown that there is an increase of glomerular volume after transplantation and that a larger glomerular volume at 4 months is associated with a better glomerular filtration rate. This adaptation mechanism is impaired in patients with chronic allograft nephropathy or in patients with high cyclosporin levels. Taken together, these data suggest that the steady improvement of renal allograft function may be partly explained by a better glomerular adaptation after transplantation because of the avoidance of the vasoconstrictive effect of anti-calcineurinic agents, and a significant decrease in the prevalence of chronic allograft nephropathy early after transplantation.
authors.affiliation: Nephrology Department, Hospital Universitari de Bellvitge, L'Hospitalet, Barcelona, Spain. 17664dsm@comb.es
authors.forename: Daniel
authors.initials: D
authors.lastname: Serón
authors.forename: Xavier
authors.initials: X
authors.lastname: Fulladosa
authors.forename: Francesc
authors.initials: F
authors.lastname: Moreso
mesh_terms: D000375:Aging; D019703:Calcineurin / Q000502:physiology; D065095:Calcineurin Inhibitors; D003404:Creatinine / Q000097:blood; D005919:Glomerular Filtration Rate; D006084:Graft Rejection; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology / Q000627:therapeutic use; D007668:Kidney / Q000098:blood supply / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology*; D007678:Kidney Glomerulus / Q000098:blood supply / Q000473:pathology / Q000503:physiopathology; D016030:Kidney Transplantation / Q000009:adverse effects*; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D011237:Predictive Value of Tests; D012307:Risk Factors; D016559:Tacrolimus / Q000494:pharmacology / Q000627:therapeutic use; D013997:Time Factors; D014019:Tissue Donors; D014661:Vasoconstriction
chemical_list: D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D003404:Creatinine; D019703:Calcineurin; D009173:Mycophenolic Acid; D016559:Tacrolimus